고정된 트윗
Meshal K. Alghanem
3.3K posts

Meshal K. Alghanem 리트윗함

Precancers in the human pancreas.
Imaged in 3D here using CODA.
More here: nature.com/articles/s4158…
About CODA: nature.com/articles/s4159…
English
Meshal K. Alghanem 리트윗함

De novo design of potent CRISPR-Cas13 inhibitors provides a strategy to rapidly design off-switches for RNA-editing systems
nature.com/articles/s4158…
English
Meshal K. Alghanem 리트윗함
Meshal K. Alghanem 리트윗함

GLP-1 drugs and cancer?
A new study shows colon cancer patients on GLP-1s had a 5-yr mortality of 15.5% vs 37.1% in non-users.
That’s MASSIVE.
Researchers say it may go beyond weight loss — GLP-1s may be reshaping inflammation, immunity, metabolism, even tumor biology.
From diabetes → obesity → heart → kidney → now possible anticancer effects.
We’re watching the start of something BIG. 🔥
#GLP1 #CancerResearch #ColonCancer #MedTwitter #RheumTwitter #Oncology #ObesityMedicine #Metabolism #Healthcare #MedicalNews #Ozempic #Wegovy @DrAkhilX @IhabFathiSulima @CelestinoGutirr @Urchilla01

English
Meshal K. Alghanem 리트윗함

Your cells (and not just the ones in your brain) remember.
Fat cells retain an “obesogenic memory” after weight loss: an energetic imprint that primes them to store again.
Viewed through the Energy Resistance Principle (ERP), this is a regulatory strategy for energy efficiency.
Rather than burning energy to reprogram tissues after each feast or famine (a costly, entropy-generating process that amplifies éR) the body encodes past flux into stable epigenetic states. This avoids unnecessary resistance, minimizes entropic waste, and optimizes energy flow.
This is LTP for fat cells: a form of long-term potentiation outside the brain. A kind of somatic “energetic” memory that spares the system from future resistance overload.
What other tissues might hold similar efficiency-promoting memories? What flux imprints are shaping your physiology right now?
🔗: nature.com/articles/s4158…

English
Meshal K. Alghanem 리트윗함

For readers interested in next-generation GLP-1-based drugs such as Lilly's oral candidate orforglipron, here's a comprehensive review from @DanielJDrucker
rdcu.be/eLlPq
nature.com/articles/s4157…

English
Meshal K. Alghanem 리트윗함

CHI3L3+ immature neutrophils inhibit anti-tumor immunity and impede immune checkpoint blockade therapy in bone metastases dlvr.it/TNjd8P

English
Meshal K. Alghanem 리트윗함

Preview @ImmunityCP
Burning the candle at both ends: ROS-mediated telomere damage drives T cell dysfunction
cell.com/immunity/fullt…
on
cell.com/immunity/fullt…

English
Meshal K. Alghanem 리트윗함

Excited to announce mBER, our fully open AI tool for de novo design of epitope-specific antibodies. To validate, we ran the largest de novo antibody experiment to date: >1M designs tested against 145 targets, measuring >100M interactions. We found specific binders for nearly half the targets, with up to 40% hit rates. Thread below:
GIF
English

@HUSSAM3idM الف مبروك قبولك يا اخوي حسام ، كل التوفيق ان شاء الله. 🌹
العربية

اللهم لك الحمد حتى ترضى ولك الحمد اذا رضيت ولك الحمد بعد الرضا , بفضل الله وتوفيقه قُبلت في البورد السعودي في تخصص طب أسنان الأسرة في جامعة الملك سعود.
اللهم بارك لي في علمي وبارك لي في عملي واجعلني مباركًا✨
#matching2024

العربية
Meshal K. Alghanem 리트윗함
Meshal K. Alghanem 리트윗함
Meshal K. Alghanem 리트윗함
Meshal K. Alghanem 리트윗함

The tumor niche can reprogram long-lived protumorigenic neutrophils dlvr.it/T377KC #immunology

English
Meshal K. Alghanem 리트윗함










